Navigation Links
STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
Date:10/19/2007

MENTOR, Ohio, Oct. 19 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that it will issue its fiscal 2008 second quarter earnings release before the market opens on October 30, 2007, followed by a conference call at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at http://www.steris-ir.com or via phone by dialing 1-888-392-9976 in the United States and Canada, and 1-517-645-6486 internationally, then referencing the password "STERIS" and the conference leader's name, "Aidan Gormley."

For those unable to listen to the conference call live, a replay will be available from 12:00 p.m. Eastern time on October 30, 2007 until 5:00 p.m. Eastern time on November 13, 2007, either over the Internet at http://www.steris-ir.com or via phone by calling 1-800-756-3940 in the United States and Canada, and 1-402-998-0796 internationally.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit http://www.steris.com.

This news release and the conference call referenced here may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in the referenced conference call may adversely impact Company performance, results, or value.


'/>"/>
SOURCE STERIS Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower ... college students who have participated in the program every summer. The 2017 Serve, ... applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... Immunotherapy ... a growing number of cancers and is touted to be the next revolution in ... thus far, has been in the form of immune checkpoint inhibitors such as PD-1 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  The leader in accelerated orthodontics, ... Sam Daher , Manal Ibrahim , ... Couchat will be the featured microlecture presenters at the ... Association of Orthodontists (AAO) Annual Session, April 21-25, 2017. ... microlectures beginning daily at 11:20 a.m. On the opening ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... , March 29, 2017 ... a report, which provides an exhaustive study of ... study, nearly 242 companies are functional in this ... competitive. With the leading companies, such as GlaxoSmithKline ... LP, focusing aggressively on various marketing strategies to ...
Breaking Medicine Technology: